| A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa (NCT06891885) | Sumitomo Pharma America, Inc. | 2026-04-16 |
| How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers (NCT07444268) | Sumitomo Pharma America, Inc. | 2026-03-26 |
| A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP) (NCT06517940) | Sumitomo Pharma America, Inc. | 2024-10-03 |
| TP-3654 Food Effect Study (NCT07492355) | Sumitomo Pharma America, Inc. | 2024-03-04 |
| A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder. (NCT06037668) | Sumitomo Pharma America, Inc. | 2023-09-08 |
| Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654 (NCT06389955) | Sumitomo Pharma America, Inc. | 2023-05-22 |
| Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (NCT05605964) | Sumitomo Pharma America, Inc. | 2023-01-28 |
| A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (NCT05467176) | Sumitomo Pharma America, Inc. | 2022-10-04 |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (NCT04988555) | Sumitomo Pharma America, Inc. | 2022-02-28 |
| A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. (NCT05169710) | Sumitomo Pharma America, Inc. | 2021-12-21 |
| Study of DSP-0390 in Patients With Recurrent High-Grade Glioma (NCT05023551) | Sumitomo Pharma America, Inc. | 2021-09-08 |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (NCT04666129) | Sumitomo Pharma America, Inc. | 2021-02-18 |
| Phase 1 Study of Oral TP-1454 (NCT04328740) | Sumitomo Pharma America, Inc. | 2020-07-08 |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols (NCT04299880) | Sumitomo Pharma America, Inc. | 2020-02-24 |
| Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy (NCT03969420) | Sumitomo Pharma America, Inc. | 2020-01-15 |
| A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis (NCT04176198) | Sumitomo Pharma America, Inc. | 2019-12-16 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL (NCT03572634) | Sumitomo Pharma America, Inc. | 2019-06-10 |
| Study of TP-3654 in Patients With Advanced Solid Tumors (NCT03715504) | Sumitomo Pharma America, Inc. | 2019-04-16 |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (NCT03604783) | Sumitomo Pharma America, Inc. | 2018-12-26 |
| A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS (NCT03593915) | Sumitomo Pharma America, Inc. | 2018-08-29 |
| First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors (NCT03429218) | Sumitomo Pharma America, Inc. | 2018-07-10 |
| A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression (NCT03543410) | Sumitomo Pharma America, Inc. | 2018-06-26 |
| A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia (NCT03627195) | Sumitomo Pharma America, Inc. | 2018-06-07 |
| A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (NCT03416335) | Sumitomo Pharma America, Inc. | 2018-06-01 |
| A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects (NCT03525405) | Sumitomo Pharma America, Inc. | 2018-05-18 |
| A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (NCT03416816) | Sumitomo Pharma America, Inc. | 2018-05-15 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (NCT03311334) | Sumitomo Pharma America, Inc. | 2017-12-14 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (NCT03149003) | Sumitomo Pharma America, Inc. | 2017-12-08 |
| Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). (NCT03298984) | Sumitomo Pharma America, Inc. | 2017-09-25 |